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Abstract 
Aim To examine whether intensive glucose control reduces complications including renal 
insufficiency, visual impairment, neuropathy, or cardiovascular disease in patients with type 2 
diabetes. 
3 
Methods Systematic review of randomized control trials and prospective observational studies 
investigating the effect of intensive blood glucose control on diabetic complications in patients 
with type 2 diabetes published between 1990 and 2007. Studies were identified using 
MEDLINE, The Cochrane Library and CINAHL. Reference lists of relevant papers were hand 
searched for further articles. 
Results Two good quality studies met inclusion criteria, UKPDS 33 and UKPDS 35. In UKPDS 
33, median HbA,c in the intensive group was 7.0% (95% Cl: 6.2-8.2) and the conventional group 
was 7.9% (95% Cl: 6.9- 8.8). The reduction in HbA1c correlated with a decrease in certain 
diabetic complications including blindness and amputation. There was no difference between 
the control and intervention groups for worsening visual acuity, absent ankle or knee reflexes, 
orthostatic hypotension, erectile dysfunction, silent Ml, absent peripheral pulses, or evidence of 
peripheral vascular disease detected by doppler. A 16% reduction in myocardial infarction was 
border line insignificant with p = 0.052. 
In UKPDS 35, for each 1% reduction in A,c level, there was an associated decrease in 
risk of 37% for microvascular endpoints, 43% for amputations or death from peripheral vascular 
disease, and 14% for myocardial infarction. The incidence of a myocardial infarction was two to 
three times that of microvascular complications around normal values of A,c, but as the A,c 
reached higher values in near the maximum range, the risk of these complications were similar. 
Conclusions Limited evidence is available to support the treatment of all patients with type 
2 diabetes with intensive blood glucose control. Age, duration of disease, co-morbid 
complications, and compliance are some of the factors to be considered in A 1 c target values 
and these should be determined on an individual patient basis. Several trials are currently 
underway to provide more insight into the benefits of intensive glucose control to near-
normal values. Studies to determine the magnitude of any benefit to lower A1c values to 
normal and below are not available. 





In the United States, diabetes is becoming increasingly common as the number of 
Americans with this disease increased from 5.8 million in 1980 to 14.7 million in 2004. Although 
some of the increase in incidence is likely accounted for by an increase in screening, diabetes 
and its complications are major health concerns.' An estimated one-sixth of all health care 
costs are accounted for by 4.5% of all people with diabetes, and approximately ninety to ninety-
five percent of patients diagnosed with diabetes have type 2 diabetes.2 
Among people 25-75 years of age, diabetes is the leading cause of end-stage renal 
disease, non-traumatic amputation, and blindness in the United States. It is also an independent 
risk factor for stroke and myocardial infarction. Complications from diabetes can be debilitating, 
so appropriate management early in the disease process is critical. 
In efforts to prevent this progression, most current guidelines recommend treating to 
goal A,c values< 7.0%, fasting blood glucose< 100 mg/dL and postprandial blood glucose 
levels between 80-150 mg/dL.',.·26'33 However, whether or not these values have been 
supported by the evidence remains uncertain. The prevailing assumption suggests that clinical 
outcomes and quality of life are improved with increasingly tight control of blood glucose to 
normal values in patients with diabetes; however, this may not be the case. Evidence from the 
Diabetes Control and Complications Trial (DCCT) has shown that tight control of blood glucose 
in patients with type I diabetes is beneficial, but it is uncertain whether or not these results can 
be extrapolated to patients with type 2 diabetes. Additionally, it is possible that most of the 
benefit from glucose control can be achieved with Hgb A1c levels in the 7-8% range rather than 
less than 7.0%.3 
This paper is a systematic review of the evidence to determine the effect and magnitude 
of intensive glucose control to near-normal levels on diabetic complications, including renal 




In the past, type 2 diabetes mostly occurred in older adults, but today it is becoming 
more prevalent in younger adults and children. This trend is likely due to increased inactivity 
and an increase in weight gain and obesity due to poor eating habits and increased 
consumption of high fat foods. Initial treatments of elevated blood sugar include changes in diet 
and increased exercise. In addition, if the patient is overweight, weight loss is necessary and 
effective. If this is not effective, then drug therapy may be initiated. 
In treating type 2 diabetes, it is often difficult to regulate blood glucose with oral 
medications alone, and therefore insulin must often be utilized as well. The use of insulin can 
cause other problems such as hypoglycemia, and weight gain, which can also be seen with 
some oral medications. 
In addition to the effect of blood glucose control on the prevention of diabetic 
complications, other interacting factors contribute to these processes. Regulation of lipid levels 
as well as blood pressure values is important. Some of the complications seen in diabetes are 
due to hypertension and hyperlipidemia; thus, the true value in controlling for blood glucose may 
not be evident without normalization of blood pressure and lipid levels. 
People with type 2 diabetes may be difficult to manage, and the harms of hypoglycemia 
complicate this problem. High blood sugars affects various organ systems and may progress to 
serious complications including blindness, kidney damage, lower-limb amputations,2 nerve 
damage, recurrent infections, and illnesses from a weakened immune system. Renal failure 
and blindness are major microvascular complications to be avoided.6 
Diabetic Complications 
Retinopathy. Retinopathy is the leading cause of blindness in patients with diabetes. 
Approximately 50% of patients with diabetes develop retinopathy within twenty years of 
developing this disease. This population also has an increased risk for the development of 
open-angle glaucoma, and cataracts. 
Neuropathy. Patients experience reduced vibratory and pinprick sensation, as well as 
decreased or absent ankle reflexes. Pain, paresthesias, or hyperesthesia also occur. The 
development of neuropathies in patients with diabetes often leads to further complications such 
as ulcers and trauma to the feet unknown to the patient because of the lack of sensation. 
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These lesions become infected in part by the lack of care to these injuries, but also in part by 
vascular insufficiency which contributes to poor healing. The development and progression of 
an infection can lead to osteomyelitis which is extremely difficult to treat in patients with diabetes 
and possibly to amputation.2 More than 60% of nontraumatic lower limb amputations are due 
to diabetes.3 
Neuropathy of the cardiac nerves most likely contributes to the large number of silent 
myocardial infarctions seen in patients with diabetes. 
Autonomic neuropathy is also responsible for erectile dysfunction which occurs in up to 
75% of men with a long history of diabetes. 
Macrovascu/ar. The development of coronary artery disease is two-fold higher in men and 
three-fold higher in women with diabetes.3 Cerebrovascular disease including stroke, 
peripheral vascular disease, and amputations are also major complications. Low HDL levels 
are associated with insulin resistance, and low HDL contributes to atherosclerosis. 
Intensive therapy 
From the results of the DCCT trial, intensive therapy consisted of multiple insulin injections, 3-4 
per day, or a continuous insulin infusion using an insulin pump. This method was used to keep 
blood glucose levels within normal limits and it correlated to a 2% reduction of the A,c levels in 
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the intervention group to 7%.5 The goals of the UKPDS also had the goal of normalizing blood 
sugar levels, but used oral agents as well in their definition of intensive therapy. The current 
inclusions of intensive therapy also include aggressive treatment for associated conditions such 
as hypercholesterolemia and hypertension. Weight loss, exercise, diet modifications, and 
frequent monitoring of plasma glucose levels are included as other intensive therapies. 
Studies have shown that glucose control in patients with type 2 diabetes decreases the 
complications from this disease, and guidelines for treatment are created based on these results. 
These guidelines recommend intensive treatment to maintain tight glycemic control and obtain 
A,c values below 7%. A summary of the guidelines is included in the appendix.33 Most of the 
evidence for type 2 diabetes, however, is either based on intermediate outcomes such as 
retinopathy and microalbuminuria, or is concluded from findings in studies of type 1 diabetes. 
The purpose of this systematic review is to examine patients with type 2 diabetes to see 
(1) whether the current available evidence supports intensive glucose control to near-normal 
levels in order to decrease or prevent diabetic complications, including renal insufficiency, visual 
impairment, neuropathy, and cardiovascular events, and (2) the magnitude of the benefit, if any, 
of achieving A,c values below 7.0%. 
Methods 
Population 
Population for review comprise all patients with type 2 diabetes and complications 
include visual impairment, renal insufficiency, neuropathy, and cardiovascular events. 
Search Strategy 
I performed a search of MEDLINE, The Cochrane Library, and CINAHL from 1990 
through September 2007 for prospective randomized control trials or observational studies in 
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English. I focused on studies that addressed blood glucose control in human subjects with type 
2 diabetes, and the occurrence of complications at varying A,c levels. Initial MeSH terms 
included "Diabetes Mellitus, Type 2" and "Hemoglobin A, Glycosylated". This search yielded 
894 articles which I further narrowed by relevance to blood glucose control. 553 articles 
remained and further narrowed by those that discussed diabetic complications with the MeSH 
subheading "complication". This resulted in 101 articles for title and abstract review. Exclusion 
of articles occurred if the primary focus of reducing the progression of complications was any 
method other than glucose control and lowering A 1 c values. Other methods include blood 
pressure control, lipid reduction. Studies where the primary outcome was to compare the 
efficacy between two drugs in lowering blood glucose, the primary outcomes were intermediates 
of clinical disease such as retinopathy, neuropathy, or nephropathy, and screening or diagnosis 
was the focus were also eliminated. Searches specific to cardiovascular disease, renal 
insufficiency, visual impairment, and nerve damage in conjunction with blood glucose control in 
type 2 diabetics resulted in smaller subsets of articles reviewed for relevance with the same 
criteria as above applied. The references for relevant papers were hand searched for further 
articles. Two papers met the outlined criteria and are the focus of this review. A summary of 
these studies is presented in table 2 below. Two other studies also addressed the purpose of 
this review and warrant discussion. This search process is outlined in diagram 1. 
Inclusion/exclusion criteria 
Articles were chosen if they addressed type 2 diabetes, diabetes management, 
complications from type 2 diabetes, effects of glucose control on complications, and the degree 
of glucose control to have an effect on complications. The articles must have measured one or 
more of the following outcomes: visual impairment, renal disease, cardiovascular disease, or 
neuropathic complications such as amputation, or sensation. Articles with intermediate 
outcomes (i.e. retinopathy, albuminuria) were excluded. I also excluded articles with the 
primary focus of drug comparisons, gestational diabetes, type 1 diabetes, and patients with 
severe pre-existing diabetic complications including end stage renal disease, amputation 
secondary to diabetic neuropathy, visual impairment, or blindness. The presence of these 
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Diagram 1: Search strategy for the effect of intensive glucose control on diabetic complications 
in type 2 diabetics. 
Numbers represent remaining studies after lettered criteria. 
a: Initial search with MeSH "Diabetes Mellitus, Type 2", "Hemoglobin A, glycosylated" yielded 
4483 results 
b. Search then limited to English, RCTs, Human subjects, 1990- September 2007 and yielded 
894 results 
c. MeSH subheading "blood glucose control" applied to search and resulted in 551 articles. 
d. Search further limited by applying subheading "complication" and its derivatives. 101 results. 
e. studies found in separate searches of renal insufficiency (32), visual impairment (12), amputation (3) 
with MeSH "Diabetes Mellitus, Type 2", "Hemoglobin A, glycosylated" and hand searched articles (5). 
f. Studies for which titles and abstracts reviewed 
g. Remaining studies for review of evidence 
h. These studies were excluded, but contained relevant information for inclusion in discussion. 
Quality Criteria 
The studies were reviewed with the quality checklist for RCT's and Observational 
Studies of Treatment Studies.10 The full checklist is included in Appendix 2 and ratings of the 
studies are listed in Table 1 below. The studies are graded on reporting, external validity, 
internal validity with respect to bias and confounding, and the use of a power calculation. 
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The studies were also graded on the suitability of the study design for assessing 
effectiveness. The categories of greatest, moderate and least characterize the suitability. A 
quality score of greatest indicates the study design contains comparison groups and prospective 
exposure and outcome measurements. Moderate indicates retrospective designs or multiple 
pre/post measurements with no concurrent comparison group. Least indicates a design with a 
single pre/post measurement, no concurrent comparison group or simultaneous measurement 
of exposure and outcome. Descriptions of these are included in Appendix 3. 
Results 
Two good quality studies examined the effect of intensive blood glucose control to near 
normal levels to decrease complications of diabetes that include visual impairment, neuropathy, 
renal insufficiency and cardiovascular events. Although studies addressed the possible benefit 
of achieving A1c values below 7.0%, neither were able to determine the magnitude of benefit. 
Additionally, two studies with intermediate outcomes are described due to the presence of some 
information relevant to this review. 
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Table 1: Quality rating of studies 
Author, Reporting External Internal Internal Power. Total Suitability of 
Year Validity Validity: Validity: · .. Quality study to 
•• 
· ..... 
. ·. ··· .. 
Elias Confounding Score assess 
I .· .. effectiveness 
UKPDS 
Group, 





2000 11/13 3/4 6/7 6/6 0 26 Greatest 
(UKPDS 
35) 
Table 2: Summary of studies 
Intensive 
therapy with 
sulfonylurea t Ml 16% (p=0.052) microvascular 
or insulin risk (retinal 
No difference in damage, Greatest 
median age: 54 visual acuity 1.1% blindness, 
(UKPDS (p=0.15), silent Ml, amputation), 
33) White/Asian/Afro- absent ankle but not 
Carribean/other reflexes 2% macrovascular 
(%) (p=0.60), absent 
82/10/8/1 knee reflexes 1% 
et al, observational therapy with with type 2 control reduces 
2000 study sulfonylurea diabetes 21% RR (95% Cl: complications 
or insulin 17-24%) diabetic 
median age: 53 endpoints, 2. No glycemic Greatest 
(UKPDS thresholds. No 
35) White/ Asian/ Afro- 14% Ml (95% Cl: specific A10 
Carribean (%) 8-21%), target 
82/10/8 recommended. 
37% (95% Cl: 33- Goal should be 
41%) microvascular to normalize. 
RR: risk reduction Ml: myocardial infarction FBG: Fasting blood glucose (mg/dl) 
Cl: confidence intervals 
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UKPD833 
In 1997 the UK Prospective Diabetes Study (UKPDS) group completed a randomized 
control trial enrolling 3867 of 7616 referred, newly diagnosed patients, ages 25-65, recruited by 
referral from general practitioners in 23 different area hospitals. Patients were followed over a 
median of 1 0 years to investigate the risk of diabetic complications in patients with type 2 
diabetes when treated with intensive blood glucose control. Intensive control aimed to have 
fasting plasma glucose levels less than 6 mm/L (108 mg/dl). The control group was treated 
with diet modifications to achieve a fasting plasma glucose less than 15 mmoi/L (270 mg/dl). 
Patients were eligible for enrollment if they had fasting plasma glucose greater than 6 
mmoi/L (108 mg/dl) on two mornings that were one to three weeks apart. This value is slightly 
above the upper limit of normal for the study reference range. Patients were excluded if any of 
the following conditions were present: ketonuria greater than 3 mmoi/L ( 17 mg/dl), serum 
creatinine greater than 175 t~moi/L (1.97 mg/dl), myocardial infarction within the last year, 
current angina or heart failure, more than one major vascular event, retinopathy requiring laser 
treatment, malignant hypertension, uncorrected endocrine disorder, an occupation preventing 
insulin therapy, severe concurrent illness limiting life expectancy or requiring extensive systemic 
treatment, an inadequate understanding of the study and its purpose, or unwillingness to enter 
the study.22 
Patients were stratified by body weight, and those not overweight randomized to 
intensive treatment with conventional diet (30%), insulin (30%), sulfonylurea (40%). 
Randomization was computer generated at a central location. Treatment assignments were 
placed in opaque, sealed envelopes that were opened sequentially. Patients went to the clinic 
every three to four months, more if necessary, for dietary counseling. Medications were added 
as necessary in the control group to maintain plasma glucose levels. Data was collected over a 
fifteen year time period. Those excluded from the study were reportedly similar in age, sex, and 
glycemic status as those accepted. The conventional and intensive treatment groups were 
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initially comparable with respect to age (mean 53 yrs), ethnicity (81% white), BMI (27.5), A1c 
(7.05%), fasting plasma glucose (8.0 mmoi/L, 144mg/dl), and plasma creatinine (81mmol/l, 0.91 
mg/dl), among other factors. The conventional group had a marginally higher percentage of 
men (1.63% vs 1.46%) and the intensive group had a slightly higher percentage of patients on 
digoxin (1.3% vs 0.9%). The potential for selection bias is minimal and controlled with 
randomization. 
This study also examined the differences in medications used to achieve glycemic 
control. Those medications used for intensive glucose control included one of three different 
sulfonylureas (chloropropamide, glibenclamide, or glipizide) or insulin. 
Approximately 4.4% of the participants were lost to follow up. The vital status was not 
available for 76 (2%) patients, with 57 from the intensive group and 19 from the conventional 
group .. An additional 91 patients (2.4%) were unable to be reached near the end of the study to 
gather final information. The randomization was done with an intensive control ratio of 70/30 to 
ensure adequate comparison, so approximately equal numbers were lost from each group. It 
was also necessary to use medications for some of the patients randomized to the conventional 
group in order to maintain a fasting plasma glucose level below 15.0 mmoi/L. Only 58% of 
person-years of follow up in the conventional group were treated with diet alone. A sulfonylurea 
was used alone or in combination with another medication in 25% of person-years of follow up, 
insulin in 16%, and metformin, alone or in combination, in 20%. Selection bias at this stage is 
also minimal since recommendations to add medications were made centrally based on glucose 
levels received. The patients were then randomized to various other medications for treatment 
as needed. 
Plasma glucose level, blood pressure, and weight were taken at each visit. The patient 
was asked about medications, hypoglycemic episodes, home blood glucose measurements, 
illness, time off work, hospitalizations, and any other symptoms including drug side effects and 
clinical events. HbA1c. plasma creatinine, lipids and insulin were measured at entry, 6 months, 1 
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year, and then annually. A random urine sample was taken yearly to measure albumin and 
creatinine. A full exam was done every three years with exams of visual acuity, 
electrocardiogram, chest x-ray, retinal photographs, lower extremity reflexes and measurements 
of autonomic neuropathy. Treatment allocation of the patients was concealed from the staff 
performing and analyzing these exams. Visual acuity, sensation and reflex, as well as renal 
failure are measured rather than solely retinopathy, micoalbuminuria, and nerve conduction 
velocity, which are intermediate outcomes. This improves the accuracy or validity of the study. 
The measurements are performed in a lab with strict protocols or with consistent staff which 
improves the reliability. 
Measurement bias could however occur with the survey questions that are asked at 
each visit. It requires the patient to recall information which may be incorrect. Also in reporting 
home glucose measurements, patients may report better blood glucose readings than they 
actually had to in order to please the physician, or make themselves look better. They may also 
be influenced when reporting side effects that may or may not be significant. The method of 
randomization is valid and data from table one on the control and intervention groups shows 
gdod comparability. Definitions of twenty one clinical endpoints were predefined including 
myocardial infarction, major stroke, blindness, and renal failure. Overall, measurement bias is 
low since most of the data is quantitative. 
Detailed eligibility criteria, randomization, and comparable matching of the groups 
eliminated many of the possible confounders. Confounders may include blood pressure control 
and lipid values since either of these may cause many of the same complications as diabetes 
and may be associated with having diabetes. The final analysis was done by intention to treat. 
The validity of the findings could be questionable since the control group received medications 
to obtain increased glucose control. However, a significant difference was detected even with 
the use of medications in the control group, indicating that the difference found may be of 
greater magnitude than the data convey. 
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Results showed a median HbA1c that was significantly lower in the intensive versus 
conventional group with values and 95% confidence intervals of 7.0% (6.2-8.2) and 7.9% (6.9-
8.8) respectively, p<0.0001. This represents an 11% decrease in the HbA1c value (from 7.9% to 
7.0%) over ten years. The reduction in HbA1c correlated with a decrease in certain diabetic 
complications including retinal damage, blindness and amputation. Those in the intensive group 
had a 25% (p=0.0099, 95% Cl: 0.06-0.93) risk reduction in microvascular endpoints compared 
to the conventional treatment group. The majority of this reduction was due to a decrease in the 
number of cases of photocoagulation treatment. There was no difference between the control 
and intervention groups for worsening visual acuity, the proportion of patients blind in both eyes, 
absent ankle or knee reflexes, orthostatic hypotension, erectile dysfunction, silent Ml, absent 
peripheral pulses, or evidence of peripheral vascular disease detected by doppler. Although the 
number of patients who developed renal failure or died from renal disease was small, a 
decrease in the percent of patients with a two-fold increase in plasma creatinine or plasma urea 
occurred by 67% and 74% respectively. A 16% reduction in myocardial infarction was border 
line insignificant with p = 0.052. 
Overall, internal validity is good, and external validity is reasonable. The average age of 
people in the study is 53 with a standard deviation of 8.6, and the population studied is also 
81% white and 61% male. The findings are not necessarily relevant to patients much older for 
reasons including the side effect of medications, and the occurrence of hypoglycemia, which 
was higher in the intensive group. Other groups of people may also have other factors 
contributing to glucose control such as environment or genetics. The mean BMI of 27 is 
marginally overweight. Obesity is one of the main causes of type 2 diabetes in America, so the 
same results may not be seen in this population due to complications of obesity. The patients in 
this study had HbA1c values around 7%, yet many patients with type 2 diabetes have values 
much higher than this. 
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The results of this study provide useful information to create guidelines for treating 
patients with type 2 diabetes. Lowering blood glucose decreased microvascular disease 
including renal failure, death from renal failure, retinal photocoagulation, and vitreous 
hemorrhage, but achieved no definitive effect on visual acuity, peripheral vascular disease, or 
nerve sensation. Benefits not directly related to clinical symptoms, included decreases in 
intermediate markers such as serum creatinie and urine albumin. Also, the study showed 
improvements in diabetic complications with a median A1c of 7.0%. However, this value was 
difficult to achieve and maintain over the ten years of the study and may not be a realistic target. 
The significance of the benefit to maintain A1c values at and below 7% remains unclear.23 
UKPDS35 
The UKPDS group performed several other embedded studies to further characterize 
the relationship between factors such as hypertension and hyperglycemia on macrovascular 
and microvascular complications in patients with type 2 diabetes.5•6•7 Of these studies, one 
specifically addresses the effect of intensive glycemic control on clinical outcomes of diabetic 
complications. The UKPDS 35 is a prospective observational study which investigated the 
development of diabetic complications over time in relation to plasma glucose. This data was 
compared to the results of the UKPDS intensive glucose control trial. 5 Any end point or death 
related to diabetes was a primary clinical aggregate outcome. Secondary aggregate outcomes 
included myocardial infarction, stroke, amputation (including peripheral vascular disease), and 
microvascular disease (primarily retinal photocoagulation). Non-fatal heart failure and cataract 
extraction were single endpoints. 
Of 5102 patients 4585 had A1c measurements taken three months after the diagnosis of 
diabetes. Information was available on 3642 (79%) of these in order to determine confounders, 
and was used to determine relative risk. Patients in the blood glucose control study with fasting 
glucose concentrations between 6.1 and 15.0 mmoi/L (270 mg/dl) were randomized into either 
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conventional treatment or intensive treatment with a sulfonylurea or insulin. Conventional 
treatment consisted mainly of diet modification. The average age was 53 years, sixty percent of 
participants were male, eighty-one percent white, BMI of 27.5 and an A,c of 7.1. 
Results were stratified by A1c value and were < 6.0% with a median value of 5.6%, 6.0% 
to 7.0% with median value of 6.5 %, 7.0% to 8.0% with median value 7.5%, 8.0% to< 9% with 
median value of 8.4%, 9.0% to 10% with median value of 9.4%, and ;;:1 0% with a median value 
of 1 0.6%. The range was 4.6 to 11.2%. 
The data presented in table 1 of the study showed good correlation between the patients 
in the two comparison groups, observational and UKPDS trial. Confounders were controlled for 
in the proportional hazards regression model used, the Cox model. Potential confounders 
accounted for include sex, age, ethnic group, smoking (current/ever/never) at the time of 
diabetes diagnosis, baseline HDL and LDL, triglycerides, presence of albuminuria after three 
months, dietary treatment, and systolic blood pressure."·7 
The results showed an adjusted incidence rate of diabetic complications that increased 
with increasing A,c values. Over the range of increasing glycemic index values, the increase in 
incidence rate for microvascular end points was greater than the incidence rate for myocardial 
infarctions. For each 1% reduction in A1c level, there was an associated decrease in risk of 37% 
for microvascular endpoints, 43% for amputations or death from peripheral vascular disease, 
and 14% for myocardial infarction. The incidence of a myocardial infarction was two to three 
times that of microvascular complications around normal values of A, 0 , but as the A,c reached 
higher values in near the maximum range (A1c of 10% or greater) , the risks were similar.30 
Other Studies 
The two studies described above use clinical outcomes to determine the relationship 
between hyperglycemia and complications related to diabetes. This is more useful in terms of 
determining how glucose control actually affects diabetic complications. Although intermediate 
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outcomes can progress to complications, they do not directly correlate with the degree of clinical 
symptoms and health deterioration of the patient. The following studies measured intermediate 
outcomes as well as clinical outcomes such as visual acuity, or neuropathy, but report 
intermediate outcomes. The findings in these studies are relevant to discuss because they 
have been used to create the guidelines in practice today, and it is important to determine 
whether the evidence in any way substantiates tight glycemic control and target HbA,c values 
below?%. 
Kumamoto Study This study focused on Japanese patients with type 2 diabetes.2' 8 In this eight 
year randomized control study, researchers determined the effects of glucose control on 
preventing diabetic complications as well as the effects of glucose control on preventing the 
progression of diabetic complications. Two intervention groups were created. Intensive insulin 
therapy for patients with type 2 diabetes, but no retinopathy or nephropathy at baseline 
comprised the first group. The effect of intensive insulin therapy on the progression of simple 
retinopathy and nephropathy (urinary albumin excretion level < 300 mg/24 hour period) at 
baseline was investigated in a second cohort. 8 
The goal of the control group was to have a fasting blood glucose level less than 
140mg/dl, and to avoid symptoms of hyperglycemia, or hypoglycemia (severe- patient required 
assistance of another person, blood glucose less than 50 mg/dl, and quick recovery after 
glucose loading or mild- associated symptoms of sweating, palpitations, hunger or blurred 
vision, blood glucose less than 50 mg/dl, and no assistance required). Levels close to 140 
mg/dL were maintained with once or twice a day injections of intermediate acting insulin. The 
intensive therapy intervention group received short acting insulin at each meal and intermediate 
acting insulin at bedtime. Target values for this group included a fasting blood glucose level 
less than 140mg/dl, a 2 hour postprandial blood glucose level less than 200 mg/dl, and HbA,c 
less than 7.0%, and a mean amplitude of glycemic excursions less than 100 mg/di.8 The 
characteristics of patients within the two groups did not differ significantly with respect to age, 
sex, duration of diabetes, BMI, urinary c-peptide excretion, HbA1c. serum cholesterol, 
triglycerides, and HDL, degree of retinopathy, urinary albumin excretion and nerve conduction 
velocity. 
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The eight year results showed that normoglycemia was nearly achieved and maintained 
for the duration of the study in the intensive intervention group as opposed to the group with 
less stringent control. Results are summarized in table 3 below. There seemed to be significant 
differences in neuropathy between the two groups with improved nerve conduction velocities in 
the group where blood glucose levels and HbA1c were lower. Intensive blood glucose control 
with insulin delayed the onset and progression of retinopathy and nephropathy as well. While 
improvement in microvascular complications seemed to be improved, no definitive conclusions 
could be drawn with regards to macrovascular complications, There was a slight increase in 
microvascular complications iri the conventional therapy group compared to the more tightly 
controlled group, but the significance could not be determined likely due to the small sample 
size used in the study. The recommendations from this study of HbA1c below 6.5%, fasting 
blood glucose below 110 mg/dL, and 2-hour postprandial glucose concentration below 180 
mg/dL were made based on the observation of no worsening retinopathy or nephropathy below 
these levels. 
The incidence of hypoglycemic episodes was also not significantly higher in the 
intervention group, with episodes in the intensive insulin control group occurring slightly more 
than one and a half times as often than in the group with conventional glycemic control. Six 
episodes were reported in the intensive group versus four in the conventional group. This is 
significantly different from the results of other studies where this difference was as high as three 
fold. 
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Table 3: Kumamoto Study Results over the eight year study period 
122±30 7.2± 1.0 90±26 3.0 2.0 
162 ± 30 9.4 ± 1.3 136 ± 35 7.0 5.0 
FBG: fasting blood glucose p < 0.05 MAGE: mean amplitude of glycemic excursions 
'Events per 100 patient years p=0.023 2Events per 100 patient years p=0.043 
It should be noted that the target values used in this study are above the more stringent 
recommended guidelines offasting blood glucose level of less than 100 mg/dl and postprandial 
levels of 80-150 mg/dl. The study population also consisted of non-obese, hypoinsulinemic 
insulin requiring type 2 diabetic patients. The study was small with only 110 subjects and they 
were all men. Also, this study is not likely not generalizable to people in America where there is 
a higher prevalence of obesity and sedentary lifestyle. The subjects in this study were actually 
quite lean, which is not characteristic of the majority of type 2 diabetic patients seen in the US. 
This study did not comment on other changes that may have been contributory to improved 
outcomes such as diet and exercise. 
In addition to an increase in the number of hypoglycemic events that may occur with 
tight glucose control using insulin, weight gain may also be a problem with intensive glucose 
control. There was an insignificant increase in BMI seen in both groups, and this increase was 
also smaller than that observed in the DCCT study.8 The authors do point out that unlike the 
case in many Western countries, the patients in this study were not hyperinsulinemic and 
therefore smaller doses of insulin could be used to achieve close to normal glycemic levels. 
This is another reason it is likely not generalizable to US patients with diabetes. The averages 
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for the HbA1c values for the two groups over eight years were 7.2% ± 1.0% in the tightly 
controlled group versus 9.4% ± 1.3% in the control group and fasting blood glucose averages 
were 122 ± 30 versus 162 ± 30 respectively. 8 With this comparison it is not clear as to whether 
the differences seen would be as significant as or equivocal to a decrease in HbA,c values that 
are much higher. It still needs to be determined whether or not a greater a health benefit is 
achieved to decrease HbA1c values from 11% and 12% to 8% and 9% than there is to reduce 
HbA1c values in patients with type 2 diabetes below 7.0%. No study has examined this question. 
Molyneaux et ai 9_An Australian study by Molyneaux, Constantino, McGill, et al was organized to 
determine the correlation between glycemic control and risk reduction in patients with type 2 
diabetes. In addition they compared these results to those found in the Diabetes Control and 
Complications Trial, which addressed the same question for patients with type 1 diabetes. Data 
on patients was taken from a database containing information on patients with type 2 diabetes 
who attended a Complications Assessment Service more than once. Patients were referred by 
their primary care physician for and initial evaluation and at varying follow-up intervals from 1-4 
years. Evaluation included retinal examination, visual acuity, morning spot urine sample to 
determine microalburninuria, and lower extremity sensory exam, as well as reflexes and pulses. 
A,c, lipids, and routine biochemistry tests were also performed. The data represented diabetic 
complications over time from initial development with respect to glycemic control. Retinopathy 
constituted any diabetic retinopathy development on retinal exam, and microabbuminuria as a 
urinary albumin concentration greater than 30mg/l. 
The study monitored 963 patients with type 2 diabetes who did not have any signs of 
retinopathy at the initial visit. These people also returned for follow-up visits. Median values of 
initial patient characteristics include age of 57.5 years, duration of diabetes 3.8 yrs (range 0.8-
8.8), A1c 7.8% (range 6.7-9.5), and current treatment with diet (27%), oral agent (63%), or 
insulin (10%). Patients had a median of 3.5 visits and a median follow-up period of 28 mos. 
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399 of these patients had no signs of microalbuminuria initially and were followed for its 
development. There was a 60% follow-up rate and the only reported difference between those 
who did follow-up with a subsequent visit and those who did not was the percent of each group 
treated for diabetes with an oral hypoglycemic agent. 63% of those who returned versus 55% of 
those who did not were using an oral agent. 
The mean of serial HbA1c values was used in calculations and the results showed a 
linear relationship between the In (HbA1c) versus both retinopathy and microalbuminuria. 
Similar results were found in the DCCT study. Risk reductions for each of these complications 
were calculated for a 10% HbA1c reduction. The annual incidence for retinopathy was 5. 7% 
(95% Cl: 4.0-7.2) and 8.3% (95% Cl: 5.7-10.9) for microalbuminuria. There was a statistically 
significant relative risk reduction, 24% (95% Cl: 16-32) associated with a 10% lower mean 
HbA1c value for retinopathy. The reduction found in the DCCT was 35% (95% Cl: 29-41 ). The 
relative risk reduction of 9% (95% Cl: -2-19) for microalbuminuria was not statistically significant. 
The DCCT trial showed a reduction of 25% (95% Cl: 19-32) for patients with type 1 diabetes. In 
regards to retinopathy, reducing the A1c value from 11% to 9.9% reduced the absolute risk by 
three cases per 100 patient years. Reducing the A1c value from 8.0% to 7.2% reduced the 
absolute risk by one case per 100 patient years. This suggests that with higher A,c values, 
there is a greater risk reduction associated with controlling blood glucose levels and lowering 
the A1c value. This trend is not seen to the same extent with microalbuminuria. An A,c reduction 
from 11% to 9.9% reduced the absolute risk 0.8 cases per 100 patient years and 0.6 cases per 
100 patient years when decreasing A1c levels from 8.0%-7.2%. Also, with A,c levels ;::8.0% and 
,;;8.0%, there was no significant difference in the risk gradient for retinopathy or 
microalbuminuria and therefore no threshold for A,c level could be determined. 
The authors concluded that the development of retinopathy is related to hyperglycemia 
in patients with type 2 diabetes though to less of an extent than seen in patients with type 1 
diabetes. The correlation between hyperglycemia and microalbuminuria was not as evident 
likely due to other factors that may relate to albumin excretion. It was also noted that they did 
not account for confounders such as blood pressure and lipid values. 
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Although this study has raised some interesting findings and tried to address the 
question of whether or not there is a limit to the benefit of reducing A,c levels, there are some 
problems. This study was not a randomized control trial, but rather an observational study that 
included beginning and end points in the analysis without a sense of the progression of disease. 
Patients were referred by their physicians for both initial and follow-up visits. Physicians may 
have referred patients they felt would be compliant more than those they felt would not follow-up. 
It was also stated that the only difference between those in the study and those lost to follow-up 
was the proportion taking oral medications, but only ranges are given as opposed to a more 
detailed, direct comparison of the groups. Also the factors used for analysis are retinopathy and 
microalbuminuria. While it is known that these conditions eventually progress to visual 
impairment and renal disease, these measurements do not necessarily correlate with clinical 
findings. Worsening retinopathy does not necessarily equal worsening vision. Data on visual 
acuity, sensation, pulses and reflexes were collected, but the results were not given in terms of 
these clinical outcomes. The patients in the study were from 50-65 years of age. These findings 
are not necessarily generalizable to patients outside this range. No information was provided 
on other factors such as gender and comorbid conditions. This is necessary for evaluating 
external validity as well. Again, this study does address an important question in the 
management of patients with diabetes, but more studies need to be performed in this area. 
26 
Discussion 
The purpose of this search was to determine whether or not the evidence supports 
intensive glucose control, and if so, how much of a benefit is realized with A 1 c values below 
7.0%. Limited published evidence is currently available to support the treatment of all patients 
with type 2 diabetes to near normal levels. 
Hyperglycemia is an independent risk factor for microvascular and macrovascular 
complications and glycemic control does improve health and decrease these complications. 
However, studies have not proven the degree of glycemic control that results in maximal benefit. 
Using normal A1c values as targets intuitively seems to be a logical goal, but achieving A1c 
values less than 7.0% in patients with diabetes may not have the degree of benefit anticipated. 
The impact of A1c values below 7.0% on complications may be insignificant as lower values are 
approached. There may also be legitimate benefit to control A1c values below 7.0%, but the 
studies are not present to provide data that will allow such determinations to be made. It is 
necessary to perform studies that examine clinical end-point outcomes, instead of intermediate 
outcomes, to determine the relationship between glucose control and improved health. The 
gain from maintaining glucose levels to normal levels may decrease as A 1 c level decreases 
below 7%. There may be more benefit to decreasing A1c values from high values (>8.0%) than 
in decreasing A 1 c values in patients from 7% to below. Furthermore, the risk of hypoglycemia 
may outweigh any benefit that can be obtained with stringent control. 
Two trials are currently underway which are looking to determine the relationship 
between glycemic control and clinical outcomes. 
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial is investigating 
whether not lowering glucose levels reduces events from cardiovascular disease. Specifically, 
whether or not lowering A 1 c values below 6.0% will decrease the rate of cardiovascular disease 
events more than lowering and maintaining A1c levels between 7% and 7.9%. The study 
population is high risk patients with type 2 diabetes. The patients are high risk due to either 
prior cardiovascular events, or the presence of cardiovascular disease risk factors. Patients 
must also have a baseline A1c value of 7.5% and above. The target for glucose control in the 
control group was chosen to avoid the increase in microvascular events seen with A 1 c levels 
above 8%. 
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This study also aims to investigate whether or not the benefits of glycemic control 
outweigh the risks of potential hypoglycemia. No chronic effects have been shown in previous 
studies, but the ACCORD trial is evaluating this in an older patient population with 
cardiovascular risk factors. The efficacy of current medications in achieving normoglycemia is 
also a goal of this study. If glucose control is not possible with current available therapies, it will 
be difficult to study intensive glycemic control. The results of this study will provide evidence of 
the relationship between glycemic control and a specific clinical outcome. Whether or not 
stringent glycemic control actually decreases the events of cardiovascular disease can be 
ascertained. This study does not however indicate which cardiovascular events it will target. 
In February 2008 the National Institute of Health announced the termination of the 
intensive blood glucose lowering treatment portion of the trial.34 257 deaths occurred in the 
intensive treatment group compared to 203 deaths in the standard treatment group. This is 
equivalent to about 3 deaths per 1,000 participants a year over a four year average. Data 
review indicated that lowering blood glucose with intensive treatment causes harm in high risk 
cardiovascular patients with type 2 diabetes. A specific cause of death has not been 
determined. The intensive group will begin the same treatment as the standard treatment group. 
These findings are strong evidence against recommendations for intensive glucose control, but 
this study population consisted of high risk patients. This result may not be true for patients with 
lower risk or who are younger, as ages ranged from 40 to 85. The trial is expected to conclude 
in June of 2009. 
The Veterans Affairs Diabetes Trial is investigating the effect of stringent glycemic 
control on cardiovascular events as well with the occurrence of any major event as the primary 
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outcome. Change in visual acuity is also an endpoint of interest. The study was started in 
December of 2000 with a 2 year accrual period and 5-7 years of follow-up. 1700 patients were 
enrolled. The subjects in this study are 41 years of age or older and have an A 1 c level ~8.3%, 
which is four standard deviations above the mean for normal levels. These patients have failed 
oral therapy and possibly insulin therapy. This study will be useful to determine the role of tight 
glucose control in preventing major cardiovascular events, as well as in determining if tight 
glucose management causes cardiovascular complications as suggested in previous studies. 
Quality of life and cost analysis is also a part of this study. 
This study observes those patients with the worse glucose control and may still not 
directly correlate to benefits or risks that may be seen in patients with less extreme 
hyperglycemic issues. While it answers an important question, studies are still needed to 
address renal failure, and neuropathies. A patient population must also be studied that is 
representative of subpopulations including various ages, complications, and degrees of 
hyperglycemic control. 
Other Evaluations based on available evidence 
Woolf, Davidson, Greenfield, et. al. also examined the benefits and risks of glycemic 
control specifically for patients with type 2 diabetes and the implications that these benefits and 
risks have on clinical practices. 26 The evidence used was obtained from randomized control 
trials and observational studies on glycemic control and the effects on microvascular and 
macrovascular complications, as well as adverse outcomes. Evidence from randomized control 
trials showed that lowering blood glucose to normal or near normal levels reduces the risk of 
microvascular and neuropathic complications although the affect on macrovascular 
complications is inconclusive. Observational studies did not show that reducing blood glucose 
levels reduced the incidence of new or worsening retinopathy, renal dysfunction, or abnormal 
electrophysiologic findings. It was also noted that most studies did not designate health 
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outcomes as a primary endpoint. Therefore, an effect could not be proved because of a lack of 
statistical power and duration in the studies. 26 
The use of intermediary observations such as retinopathy does not necessarily correlate 
with the degree of visual deterioration, which is the outcome of importance. Analysis of the 
evidence using retinopathy as an outcome as opposed to visual acuity therefore does not 
accurately predict the affect of the degree of blood glucose control. However, in both the control 
and intervention groups in the DCCT and UKPDS trials, the occurrence of end stage 
microvascular complications including blindness, amputation, and end stage renal disease was 
relatively uncommon. 19 This may account, at least in part, for the reason these values are not 
used. The study length would need to be much longer to capture, or a different study population 
used. The alternative is that normalization of blood glucose has beneficial health outcomes in 
reducing blindness, neuropathy and renal failure, but the risks outweigh the benefits with goals 
that are too stringent. 
The conclusions drawn by Woolf, Davidson, Greenfield, et al. emphasize that several 
factors must be taken into consideration when determining the degree of blood glucose 
reduction in order for a particular patient to receive maximal health benefits. This degree will 
vary by patient and is dependent on the state of overall health of the patient including the life 
expectancy as well as the presence of a comorbid disease. The development of symptomatic 
disease from microvascular complications takes years to develop, so it is necessary to 
determine whether or not the risk of complications within a certain time frame warrants a 
particular level of blood glucose control. 26 The risk of occurrence and degree of severity of 
hypoglycemia is also important. The risk of hypoglycemia to a degree that causes further 
complications or a decrease in quality of life as well as complications caused by the medications 
themselves should be considered. Serious, although uncommon, complications include 
hepatotoxicity or lactic acidosis. Weight gain caused by some medications also may also be an 
issue for some patients. It is uncertain as to how the amount of weight gain observed affects 
overall outcomes. 
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Complications from diabetes can result in impaired vision or neuropathy can impair a 
patient's ability to recognize hypoglycemia as well as one's ability to adjust medication doses. 
Insulin overdose can occur in patients who have renal disease secondary to a decrease in 
breakdown of insulin. These reasons make it necessary to modify the desired level of blood 
glycemic control. Determining the level of benefit from glucose control is also complicated 
because the degree of benefit is related to the patient's baseline disease severity with respect to 
preexisting microvascular complications, and A1c value. 26 
Other considerations for guideline development 
In many studies, patients with significant microvascular disease were excluded from the 
trials. Therefore, decreases seen in microvascular complications is relevant to patients with 
none or mild microvascular complications from diabetes and without other medical issues.19 
Similar improvements in microvascular complications secondary to diabetes can not be 
A large percentage of the population who have type two diabetes have A1c values above 9.5 
percent. For this population it may be more beneficial in the management of their diabetes to 
lower the A1c values to moderate levels. Greater absolute health benefits are seen when 
hyperglycemia which is increased substantially is reduced compared to the same magnitude of 
reduction in a person with hyperglycemia that is moderate and below. It is possible that there is 
more value in lowering patients with A1c values > 9.5 to less than 9.5, than to lower patients with 
moderate glycemic levels to normal values.26 There is disagreement in the literature as to 
whether or not thresholds exist for diabetic complications. Therefore, the assumption that 
decreasing A1c values below 7.0 is of benefit is less clear. Although it seems that patients with 
the highest glycemic abnormalities would receive the most benefit in reducing hyperglycemia, 
data shows that glucose control at any level in the patient with diabetes reduces complications. 
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3° Further research is needed in this area. The cost of achieving lower values may far outweigh 
any benefit that may be gained. A specific recommendation to implement for the general 
population of patients with diabetes does not take into account several of the above mentioned 
factors, including life expectancy, co-morbidities, and absolute health benefit. 
Hyperglycemia over a sustained period of time leads to several complications. The 
progression to blindness, renal failure, nerve damage, and cardiovascular events is based on 
several factors including the degree and period of exposure to hyperglycemia. This progression 
is often monitored by intermediates that include retinal changes on visual examination, 
microalbuminuria, and nerve conduction velocities. These intermediates are useful for 
determining worsening disease, but these measures do not indicate the magnitude of worsening 
disease. Current guidelines are based on evidence related to improvement in these 
intermediate outcomes. 
The implications of these guidelines not only directly affect the health of patients with 
diabetes, but also shape the way treatment is provided. Pay for performance measures are 
based on the use of certain guidelines. Physicians must meet certain standards and have 
certain patient outcomes based on set guidelines. Treating to achieve laboratory values risks 
neglecting possible unique needs of the individual patient and may not improve the quality of life. 
The issues of duration of diabetes and age are important factors in determining the degree 
of control. The length of time and the magnitude of which a patient has had elevated blood 
glucose levels are the main determinates of the development of microvascular complications. 28 
Intensive control may be suitable for younger type 2 diabetic patients, and tighter control may 
prove to have a larger effect in patients who have had the disease for many years. However, it 
is likely more beneficial to control blood glucose earlier in the diagnosis in order to prevent 
development of neuropathy, nephropathy, or retinopathy assumed in patients with severe 
disease. Definitive answers to these issues as well as the effects on macrovascular disease 
have yet to be answered. 
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As mentioned above in the ACCORD trial, it is necessary to make sure that it is possible 
to achieve the targets set in guidelines with current available therapies. It is also important to 
recognize the role of other factors such as the patient's lipid profile in microvascular and 
macrovascular disease and making certain that glucose control is primarily responsible for 
complications. The use of a large portion of health resources are used in diabetes management 
and it is essential that the intended benefit is realized. New data from future studies will 
hopefully make treatment goals more clear and lead to appropriate allocation of resources and 
patient care. 
Some conclusions in favor of a benefit for aggressive blood glucose control are based 
on modeling. In particular, the Markov model has been used to extrapolate data from type 1 
diabetic studies and predict the effects of varying degrees of glucose control in patients with 
type 2 diabetes.22 Increasing costs of more aggressive diabetes control necessitates the need 
to determine if a true health benefit exists for aggressive control. Some studies report a 
decrease in the risk of microvascular complications by 40% for every one point decrease in 
percentage point in A, c. 2 With this generalization it is important to determine whether this 
benefit occurs for all values of A1c. or if there reaches a point at which further decreases in A,c 
do not correlate to this degree of benefit, if any at all. 
It is important to remember that many people have other health problems that 
complicate the effects of their diabetes mellitus on various organ systems and must be 
considered in developing therapies for diabetes management. 
As is the case with treatment for many other illnesses, older adults often present special 
challenges.22 Polypharmacy from treatment of multiple comorbidies is often present, as well as 
decreased access to healthcare secondary to socioeconomic status and or social isolation.22 
Patients may be unable to afford all of their medications and may not follow their regimen as 
instructed. There is also a higher prevalence of depression that can affect one's ability to 
properly manage this illness, leading to worse blood glucose control and poorer overall health 
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outcomes.22 With or without depression, mental confusion increases the likelihood of improper 
medication administration that could lead to hypoglycemia and adverse effects. 
The presence of disability from neuropathies or arthritic joint changes also affects overall 
health. The signs of hypoglycemia in elderly patients are often confusion, dizziness, and 
delirium, as opposed to more adrenergic side effects. 22 Various therapies, both oral and with 
insulin have different effects on hypoglycemia, and can be especially dangerous in patients with 
impaired renal function, which can occur naturally in older patients irrespective of their diabetic 
state and level of glucose control. 
Regulation of blood sugar to normal values requires more than diet and exercise in most 
type 2 diabetics, and complications from oral medications such as hypoglycemia and insulin 
must be taken into account. The age of onset and duration of diabetes in the patient contributes 
to the plan and goals for treatment. Mixed information exists as to the benefits of glucose 
control in people who have recently developed this metabolic disorder and those who have 
been living with diabetes for several years.4 
Limitations 
A major limitation is the lack of randomized control trials available that address the 
particular question. However, two trials are currently underway as noted above. The search 
criteria eliminated any studies with drug comparisons as the main focus. These studies may 
offer some information on the topic and indirectly answer the questions. This could be 
examined in a future review. 
Future studies should include a patient population representative of various ages, 
complications, and degrees and duration of hyperglycemic control. Primary outcomes that are 
clinical macrovascular and microvascular complications are necessary. If evidence shows that 
the benefit to tight glycemic control outweighs the risk of hypoglycemia, therapies will need to be 
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created that are effective in order to achieve normal levels of control. In addition, the degree of 
benefit to normalization of glucose levels should be significant enough to warrant 
implementation into practice as well. 
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Quality Checklist for RCTs and Observational Studies 
(used in the AHRQ study of perinatal depression and based on a Methodological Quality 
checklist developed by Downs and Black, J Epidemiology and Community Health, 1998). 
Reviewer's initials ____ _ 
First Author ____ _ Journal: _____________ _ 
Year published __ 
Reporting 
Is the hypothesis/aim/objective of the study clearly 
described? 
2. Is the underlying theory described? 
3. Are the main outcomes to be measured clearly 
described in the Introduction or Methods section? 
4. Are the characteristics of the study population 
included in the study clearly described? 
5. Are the interventions under-study clearly described? 
6. Was exposure to the intervention measured? 
7 Are the distributions of principal confounders in 
each group of study participants to be compared 
clearly described? 
8. Are the main findings of the study clearly described? 
9. Does the study provide estimates of the random 
variability (e.g., standard error, standard deviation, 
confidence intervals, inter-quartile range) in the data 
for the main outcomes? 
10. Have all important adverse events/negative outcomes 
that may be a consequence of the intervention been 
reported? 
II. Have the characteristics of study participants lost to 
follow up been described? 
12 
Have actual probability values been reported (e.g., 
0.035 rather than <0.05) for the main outcomes 








Yes P* No 







Total Reporting score: __ 
*P ~ Partially U/D = Unable to Determine 
Yes No U/D 
External Validity 
13 Were the study participants asked to participate 1 
representative of the entire population from which 
they were recruited? 
14. Were study participants who agreed to participate 1 
representative of the entire population from which 
they were recruited? 
15. Were the staff, places, and facilities where the study I 
participants received the intervention representative of 
the intervention the majority of subjects receive? 






Total External Validity Score: __ _ 
Internal Validity-Bias Yes No U/D 
Answer this 17 and 18 only if this was a 
randomized controlled trial: 
17. Was an attempt made to blind study participants to the 1 0 0 
intervention they received? 
18. Was an attempt made to blind those measuring the I 0 0 
main outcomes of the intervention? 
Answer alternative 17 and 18 if this was not a 
randomized controlled trial: 
17. Were appropriate methods used to adjust for the 1 
differences between groups with and without the 
intervention (to control for selection bias)? 
18. Were appropriate methods used to account for any 1 
biases related to differential ascertainment of the 
outcome in groups with or without the intervention? 
19. If any of the results of the study were based on "data 1 
dredging," was tbis made clear? 
20. In trials and cohort studies, do the analyses adjust for I 
different lengths of follow-up of study participants, or 
in case-control studies, is the time period between the 
intervention and outcome the same for cases and 
controls? 
21. Were the statistical tests used to assess the main 1 
outcomes appropriate? 
22. Was compliance with the intervention reliable? 1 
















Total Bias Score: __ _ 
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Internal Validity- Confounding Yes No vm 
24. Were the study participants in the different I 0 0 
intervention groups (trials and cohort studies) or were 
the cases and controls (case-control studies) recruited 
from the same population? 
25. Were study participants in the different intervention 1 0 0 
groups (trials and cohort studies) or were the cases 
and controls (case-control studies) recruited over the 
same period of time? 
26. Were study participants randomized to intervention 1 0 0 
groups? 
27. Answer this Q.27, if randomization occurred: was 1 0 0 
the randomized intervention assigrnnent concealed 
from both study participants and intervention staff 
until recruitment was complete and irrecoverable? 
27. Answer this Q.27, if randomization did not occnr: 1 0 0 
were study participants in the research or evaluation, 
unaware of the study hypotheses? 
28. Was there adequate adjustment for confounding in the 1 0 0 
analyses from which the main findings were drawn? 
29. Were losses of study participants to follow-up taken 1 0 0 
into account? 
Total Confounding Score: 
Power 
30. Did the study mention having conducted a power analysis to determine the sample size needed to 
detect a significant difference in effect size for one or more outcome measures? 
No 
Yes, one measure 
Yes, two or more measures 
*P ~Partially 




Total Power Score 
Total Quality Score: ---=--
(sum of all domain scores) 
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Instructions for Select Questions for the Quality Checklist for RCTs and Observational 
Studies 
2. If the authors describe the formative research, theoretical basis(es) or constructs upon which the 
intervention was developed the question should be answered yes. 
3. If the main outcomes are first mentioned in the Results section, the question should be answered 
no. 
4. In cohort studies and trials, inclusion and/or exclusion criteria should be given. In case control 
studies, a case-defmition and the source for controls should be given. 
5. Interventions and placebo (where relevant) that are to be compared should be clearly described. 
7. Give one point if some confounders are described and two only if most of these principal 
confounders are described. 
8. Simple outcome data (including denominators and numerators) should be reported for all major 
findings so that the reader can check the major analyses and conclusions. (This question does not 
cover statistical tests that are considered below). 
9. In non-normally distributed data the inter-quartile range of results should be reported. In normally 
distributed data the standard error, standard deviation or confidence intervals should be reported. 
If the distribution of the data is not described, it must be assumed that the estimates used were 
appropriate and the question should be answered yes. 
10. This should be answered yes if the study demonstrates that there was a comprehensive attempt to 
measure adverse events/negative outcomes of the intervention. 
II This should be answered yes where there were no losses to follow-up or where losses to follow-
up were so small that findings would be unaffected by their inclusion. This should be answered 
no where a study does not report the number of patients lost to follow-up. 
13. The study must identify the source population for study participants and describe how the study 
participants were selected. Study participants would be representative if they comprised the entire 
source population, an unselected sample of consecutive participants, or a random sample. 
Random sampling is only feasible where a list of all members of the relevant population exists. 
Where a study does not report the proportion of the source population from which the study 
participants are derived, the question should be answered as unable to determine. 
14. The proportion of those asked who agreed should be stated. Validation that the sample was 
representative would include demonstrating that the distribution of the main confounding factors 
was the same in the study sample and the source population. 
15. For the question to be answered yes, the study should demonstrate that the intervention was 
representative of that in use in the source population. The question should be 
answered no if, for example, the intervention was undertaken in a clinically located site in whlch 
only subjects participating in clinical care might have participated in the intervention. 
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17. For randomized studies where the subjects would have no way of !mowing which intervention 
they received, this should be answered yes. 
18. For randomized studies where the researchers would have no way of !mowing which 
intervention subjects received, this should be answered yes. 
For non-randomized studies, if methods were used to adjust for initial differences between 
groups, the answer should be yes. 
18. For non-randomized studies, if the same methods were used for ascertainment of the outcome 
in both groups, the answer should be yes. 
19. Any analyses that had not been planned at the outset of the study should be clearly indicated. If 
no retrospective unplanned subgroup analyses were reported, then answer yes. 
20. Where follow-up was the same for all study subjects the answer should be yes. If different lengths 
of follow-up were adjusted for by, for example, survival analysis the answer should be yes. 
Studies where differences in follow-up are ignored should be answered no. 
21. The statistical techniques used must be appropriate to the data. For example, nonparametric 
methods should be used for small sample sizes. Where little statistical analysis has been 
undertaken but where there is no evidence of bias, the question should be answered yes. If the 
distribution of the data (normal or not) is not described it must be assumed that the estimates used 
were appropriate and the question should be answered yes. 
22. Where there was non compliance with the allocated treatment or where there was contamination 
of one group, the question should be answered no. For studies where the effect of any 
misclassification was likely to bias any association to the null, the question should be answered 
yes. 
23. For studies where the outcome measures are clearly described, the question should be answered 
yes. For studies which refer to other work or that demonstrates the outcome measures are accurate, 
the question should be answered as yes. 
24. For example, subjects for all comparison groups should be selected from the same population. 
The question should be answered unable to determine for cohort and case control studies where 
there is no information concerning the source of subjects s included in the study. 
25. For a study which does not specify the time period over which subjects were recruited, the 
question should be answered as unable to determine. 
26. Studies which state that subjects were randomized should be answered as yes except where 
method of randomization would not ensure random allocation. For example, alternate allocation 
would score no because it is predictable. 
27. If randomization occurred, and assignment was concealed from subjects but not from staff, it 
should be answered no. 
27. If randomization did not occur, if methods used ensure that those in the intervention group and 
those in the comparison group were unaware of the study hypotheses, then the answer should be 
yes. 
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28. This question should be answered no for trials if: the main conclusions of the study were based on 
analyses of treatment rather than intention to treat; the distribution of known 
confounders in the different treatment groups was not described; or the distribution of known 
confounders differed between the treatment groups but was not taken into account in the analyses. 
In non-randomized studies if the effect of the main confounders was not investigated or 
confounding was demonstrated but no adjustment was made in the fmal analyses the question 
should be answered as no. 
29. If the numbers of patients lost to follow-up are not reported, the question should be answered as 
unable to determine. If the proportion lost to follow-up was too small to affect the main findings, 
the question should be answered yes. 
SOURCE: Based on a modified version of the form from Downs SH, .Black N. The feasibility of creating a checklist for the assessment of the 




Suitability of study design for assessing effectiveness in the Guide to Community Preventive 
Services 
Suitability Attributes 
Greatest Includes designs with concurrent 
comparison groups and prospective 
measurement of exposure and outcome 
Moderate Includes all retrospective designs or 
multiple pre or post measurement designs 
with no concurrent comparison group 
Least Includes single pre and post measurement 
designs and no concurrent comparison 
group designs or exposure and outcome 
measured in a single group at the same 
point in time 
SOURCE: Based on a modified version of the form from Downs SH, Black N. The feasibility of creating a checklist for the assessment of the 
methodological quality both of randomized and non-randomized studies ofhealth care interventions. J Epidemiol Community Health, 
1998;52:377-87 
